Mexico Pharmaceuticals Report - November 2025

Abstract

Mexico’s pharma sector is poised to expand despite persistent hurdles around procurement and patent protection. Demand for cutting-edge therapies targeting chronic conditions is climbing, and as Latin America’s second-largest market, Mexico offers sizable openings for firms developing innovative medicines. That said, relatively low per-capita drug spending could limit widespread adoption of branded, patented products, likely boosting the role of generics. At the same time, government initiatives to bolster domestic manufacturing are expected to spur more cross-border partnerships, with a particular focus on technology transfer.